The Latest Analyst Ratings for Aclaris Therapeutics
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target for ACRS is $29.43, which is a significant increase from the previous target of $18.00. The high target is $43.00 and the low is $2.00. The increase in the average price target suggests a positive outlook from analysts.
November 14, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics has received positive analyst ratings, with an average 12-month price target of $29.43, marking a 63.5% increase from the previous target.
The substantial increase in the average price target for ACRS reflects a strong positive sentiment among analysts, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100